ASH 2020 | Eltrombopag for CMML patients with thrombocytopenia
Raphael Itzykson, MD, PhD, Saint-Louis Hospital AP-HP, Paris, France, outlines the results of a Phase II study investigating eltrombopag, a thrombopoietin receptor agonist, for patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia. The study found that treatment with eltrombopag was safe for CMML patients with severe thrombocytopenia and no marrow blast excess, and could thus help manage a situation at risk of bleeding such as a scheduled surgical procedure. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Raphael Itzykson, MD, PhD, has received research funding from Janssen, Novartis and Oncoethix (now Merck); has received honoraria from Sanofi, BMS and Celgene; and has done consultancy work with Novartis, Otsuka Pharma, Jazz Pharmaceuticals, Karyopharm and StemLine.
